GRAIL, Inc. (GRAL) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right. Hello, everybody. Good to see everybody. Thank you all so much for coming. Um, we have A great day for you today. And hopefully many of you will also take our tour of the lab, which will be incredible. But again, it's a pleasure to be here. We're thrilled to host an analyst day. I think this is officially our first in-person real effort here. So it's terrific to have you all. So we're going to go to a set of disclosures, which you're all familiar with. I won't Did I go too far? I won't read any of them, but just make sure if you have any questions about any of this, please come to us. And now I'm going to introduce our CEO, Bob Ragusa, who's going to give some introductory remarks. So thanks, everyone, for joining us today. I'm sorry I'm not able to join you there in person, but that does not diminish my excitement for you to be with the GRAIL team at our centralized lab in Research Triangle Park, North Carolina. I'd encourage you to spend time with our leaders and various experts in attendance and enjoy the guided tour of our lab. The lab is an operational hallmark in our endeavor for population scale, multi cancer, early detection. Our goal today is to share with you key highlights of the business and the tremendous progress that we have made as a public company since June of last year. We will also provide access to some critical experts. These are the physicians who designed and ran our key studies and the physicians who are on the front lines today using the gallery test with their patients. We've got a very packed agenda. Aaron and Josh will go through a brief business from you followed by a review of Pathfinder 2 results and the NHS study design and anticipated milestones by Dr. Nima Navavizadeh and Professor Peter Ciccini. We will have a Q&A sessio...